SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx reported Q3 2026 revenue of $173M (up 8% YoY from $160M) and…

Ultragenyx Pharmaceutical Inc. · PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

Ultragenyx reported Q3 2026 revenue of $173M (up 8% YoY from $160M) and a net loss of $118M ($1.16 per share), narrower than the $180M loss a year ago. The company announced a 20% headcount reduction, termination of two pipeline programs (GTX-102, UX701), and expects full-year GAAP profitability in 2027. Two FDA approvals (GENGLYCOS, FAYUVI) were received, and two Priority Review Vouchers were sold for a combined $413M. The EPS of -$1.16 missed the consensus estimate of -$0.75, a miss of 54.7%.

  • Q3 2026 total revenue $173M vs $160M YoY (+8.1%)
  • Net loss $118M ($1.16 per share) vs $180M ($1.81) YoY
  • EPS of -$1.16 missed consensus of -$0.75 (54.7% miss)
  • Revenue of $173M missed consensus of $183.7M (5.8% miss)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access